Stockreport

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Axsome Therapeutics, Inc.  (AXSM) 
Last axsome therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: axsome.com
PDF Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuros [Read more]